Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M. Sestak I, et al. Among authors: mallon e. JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524. JAMA Oncol. 2018. PMID: 29450494 Free PMC article. Clinical Trial.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q, López-Knowles E, Cheang MCU, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists. Gao Q, et al. Among authors: mallon e. Breast Cancer Res. 2019 Dec 31;22(1):2. doi: 10.1186/s13058-019-1223-z. Breast Cancer Res. 2019. PMID: 31892336 Free PMC article. Clinical Trial.
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Dowsett M, et al. Among authors: mallon e. J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28. J Clin Oncol. 2008. PMID: 18227529 Clinical Trial.
Predictive algorithms for adjuvant therapy: TransATAC.
Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J. Dowsett M, et al. Among authors: mallon e. Steroids. 2011 Jul;76(8):777-80. doi: 10.1016/j.steroids.2011.02.032. Epub 2011 Apr 4. Steroids. 2011. PMID: 21470560
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. Cuzick J, et al. Among authors: mallon e. J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990413
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Gao Q, López-Knowles E, U Cheang MC, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists. Gao Q, et al. Among authors: mallon e. JNCI Cancer Spectr. 2018 May 22;2(2):pky005. doi: 10.1093/jncics/pky005. eCollection 2018 Apr. JNCI Cancer Spectr. 2018. PMID: 31360844 Free PMC article.
Assessment of HER2 status in breast cancer: why, when and how?
Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R. Dowsett M, et al. Among authors: mallon e. Eur J Cancer. 2000 Jan;36(2):170-6. doi: 10.1016/s0959-8049(99)00264-6. Eur J Cancer. 2000. PMID: 10741274 Review.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28. Lancet. 2011. PMID: 21802721 Free PMC article.
214 results